Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs

References

• Rehfeld JF. Gastrointestinal hormone research – with a Scandinavian annotation. Scand J Gastroenterol. 2015;50:1–679.
   Web of Science ®Google Scholar
• Rehfeld JF. Gastrointestinal hormones and their targets. Adv Exp Med Biol. 2014;817:157–175.
   PubMed Web of Science ®Google Scholar
• Larsson LI, Goltermann N, de Magistris L, et al. Somatostatin cell processes as pathways for paracrine secretion. Science. 1979;205:1393–1395.
   PubMed Web of Science ®Google Scholar
• Kumar U, Grant M. Somatostatin and somatostatin receptors. Results Probl Cell Differ. 2010;50:137–184.
   PubMedGoogle Scholar
• Chen D, Zhao CM, Håkanson R, et al. Altered control of gastric acid secretion in gastrin-cholecystokinin double mutant mice. Gastroenterology. 2004;126:476–487.
   PubMed Web of Science ®Google Scholar
• Cao Y, Cao X, Liu XM. Expression of cholecystokinin2-receptor in rat and human L cells and the stimulation of glucagon-like peptide-1 secretion by gastrin treatment. Acta Histochem. 2015;117:205–210.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–165.
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–1439.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, NN8022-1922 Study Group, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314:687–699.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Smits MM, Tonneijck L, Muskiet MH, et al. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes Obes Metab. 2016;18:1217–1225.
   PubMed Web of Science ®Google Scholar
• Li M, Yang Y, Jiang D, et al. Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Medicine. 2017;96:e8161.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Buse JB, Azeem R, et al. Efficacy and safety of ITCA 650, a novel drug-device GLP-1 receptor agonist, in type 2 diabetes uncontrolled with oral antidiabetes drugs: the FREEDOM-1 Trial. Diabetes Care. 2018;41:333–340.
   PubMed Web of Science ®Google Scholar
• Waldrop G, Zhong J, Peters M, et al. Incretin-based therapy in type 2 diabetes: an evidence based systematic review and meta-analysis. J Diabetes Complications. 2018;32:113–122.
   PubMed Web of Science ®Google Scholar
• Halawi H, Khemani D, Eckert D, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017;2:890–899.
   PubMed Web of Science ®Google Scholar
• Wank SA. Cholecystokinin receptors. Am J Physiol. 1995;269:G628–G646.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. Cholecystokinin-from local gut hormone to ubiquitous messenger. Front Endocrinol (Lausanne). 2017;8: Art. 47.
   PubMed Web of Science ®Google Scholar
• Asmar M, Bache M, Knop FK, et al. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? J Clin Endocrinol Metab. 2010;95:2367–2375.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clin Chem. 1998;44:991–1001.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Sun G, Christensen T, et al. The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33. J Clin Endocrinol Metab. 2001;86:251–258.
   PubMed Web of Science ®Google Scholar
• Keller J, Trautmann ME, Haber H, et al. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept. 2012;179:77–83.
   PubMedGoogle Scholar
• Ben-Shlomo S, Zvibel I, Rabinowich L, et al. Dipeptidyl peptidase 4-deficient rats have improved bile secretory function in high fat diet-induced steatosis. Dig Dis Sci. 2013;58:172–178.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Federspiel B, Agersnap M, et al. The uncovering and characterization of a CCKoma syndrome in enteropancreatic neuroendocrine tumor patients. Scand J Gastroenterol. 2016;51:1172–1178.
   PubMed Web of Science ®Google Scholar
• Wang DQ, Schmitz F, Kopin AS, et al. Targeted disruption of the murine cholecystokinin-1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis. J Clin Invest. 2004;114:521–528.
   PubMed Web of Science ®Google Scholar
• Kopin AS, Lee YM, McBride EW, et al. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA. 1992;89:3605–3609.
   PubMed Web of Science ®Google Scholar
• Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev. 2006;86:805–847.
   PubMed Web of Science ®Google Scholar
• Kopin AS, McBride EW, Schaffer K, et al. CCK receptor polymorphisms: an illustration of emerging themes in pharmacogenomics. Trends Pharmacol Sci. 2000;21:346–553.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B, Gugger M, et al. Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue. Gastroenterology. 2003;125:98–106.
   PubMed Web of Science ®Google Scholar
• Konno K, Takahashi-Iwanaga H, Uchigashima M, et al. Cellular and subcellular localization of cholecystokinin (CCK)-1 receptors in the pancreas, gallbladder, and stomach of mice. Histochem Cell Biol. 2015;143:301–312.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. Why cholecystokinin and gastrin are also incretins. Cardiovasc Endocrinol. 2016;5:99––101.
   Google Scholar
• Rehfeld JF. CCK, gastrin and diabetes mellitus. Biomarkers Med. 2016;10:1125–1127.
   PubMed Web of Science ®Google Scholar
• Suarez-Pinzon WL, Power RF, Yan Y, et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes. 2008;57:3281–3288.
   PubMed Web of Science ®Google Scholar
• Fosgerau K, Jessen L, Lind Tolborg J, et al. The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice. Diabetes Obes Metab. 2013;15:62–71.
   PubMed Web of Science ®Google Scholar